Relapsed/refractory diffuse large B-cell lymphoma

This early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…

This study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…

This study tests whether giving additional antibody drugs (mosunetuzumab or glofitamab plus obinutuzumab) after CAR-T cell therapy can improve outcomes for people with relapsed or refractory large B-cell lymphoma. About 23 participants will receive the combination to see if it le…

Researchers are testing an experimental drug called epcoritamab in adults with diffuse large B-cell lymphoma or classic follicular lymphoma that has come back or stopped responding to earlier treatments. The trial gives the drug as an injection under the skin in increasing doses,…

This study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it …

This phase 2 trial tests a combination of the targeted drug polatuzumab vedotin with standard chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide) as an initial salvage therapy for patients with diffuse large B-cell lymphoma that has relapsed or not responded to treat…

This early-phase trial is testing a new treatment called JNJ-90009530, a type of CAR-T cell therapy that targets a protein called CD20 on lymphoma cells. The study includes 21 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have already tried other treatments. …

This early-stage trial tests an investigational drug called ABBV-319 in about 154 adults with certain B-cell cancers (diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The study has two…

This early-phase trial tested adding carfilzomib to a standard chemotherapy regimen (R-ICE) for adults with diffuse large B-cell lymphoma that returned or didn't respond to prior treatment. The main goals were to find the safest dose of carfilzomib and see how well the combinatio…

This early-phase trial is testing a new treatment called KITE-197 for people with large B-cell lymphoma that has come back or not responded to other treatments. KITE-197 is made from a patient's own immune cells, which are modified in a lab to better attack cancer cells. The stud…

This early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and vorinostat (Zolinza)—in people with certain lymphomas that have returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while vorin…

This early-phase trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. The therapy in…

This early-stage trial is testing whether a combination of tumor-specific immune cells (TAA-T) and the drug nivolumab can safely help people with lymphoma that has returned or not responded to treatment. Participants receive two infusions of TAA-T cells along with nivolumab, whic…

This study tests whether adding the drug ibrutinib to standard chemotherapy before and after a stem cell transplant helps people with a specific type of lymphoma (activated B-cell diffuse large B-cell lymphoma) that has returned or not responded to treatment. About 94 participant…

This phase 2 trial tests whether adding isatuximab to standard stem cell transplant procedures can help the immune system better fight multiple myeloma and certain lymphomas. Participants are randomly assigned to receive either standard transplant care alone or isatuximab plus st…

This early-stage trial tests a new three-drug combination (ibrutinib, rituximab, and bendamustine) in adults with certain types of non-Hodgkin lymphoma that have come back after prior treatment. The main goal is to find the safest dose of ibrutinib when given with the other two d…

This phase 3 trial tests whether adding brentuximab vedotin to two standard drugs (lenalidomide and rituximab) helps people with diffuse large B-cell lymphoma that has returned or not improved after at least two prior treatments. About 239 participants will receive either the add…

This phase II trial tests the drug pemigatinib (Pemazyre) in 27 adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell and marginal zone lymphoma. Participants take one pill daily in 28-day cycles. The main goal is to see if the drug can shrink tum…

This trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 2…

This study tests whether adding the oral drug selinexor to standard chemotherapy (R-GDP) can help people with relapsed or refractory diffuse large B-cell lymphoma who cannot receive a stem cell transplant or CAR-T therapy. About 500 participants will receive either selinexor at o…

This early-phase trial is testing whether combining three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody (rituximab or obinutuzumab)—is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. The study involves …

This study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…

This early-phase trial is testing a combination of the immunotherapy drug atezolizumab, two chemotherapy drugs (gemcitabine and oxaliplatin), and the targeted antibody rituximab in 24 patients with transformed diffuse large B-cell lymphoma that has come back or stopped responding…

This study aimed to test a new CAR-T cell therapy that targets a protein called Igβ on cancer cells in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The trial planned to enroll patients who had already tried at least two other treatments. However, the study …

This study tests a new treatment for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The treatment combines two drugs (tafasitamab and lenalidomide) with standard chemotherapy, followed by a stem cell t…

This early-phase trial is testing a combination of two drugs, ibrutinib and lenalidomide, in people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and understand side effects. About 39 participants with d…

This phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…

This early-phase study tests a new two-drug combination (pevonedistat and ibrutinib) in adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effec…

This study tests whether a new drug combination (loncastuximab tesirine plus rituximab) works better than standard chemotherapy for adults with diffuse large B-cell lymphoma that has returned or not improved after initial treatment. About 440 participants will be randomly assigne…

This phase 2 trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on lymphoma cells, aiming to prevent the cancer from escaping treatment. It involves 100 adults with relapsed or refractory large B-cell lymphoma who have not responded to standard…

This early-phase trial tests a new approach for patients with aggressive B-cell lymphoma that has come back after treatment. Researchers take a patient's own immune cells (T cells), modify them in the lab to better recognize and kill lymphoma cells, and give them back after a sta…

This phase 2 trial is testing an experimental cell therapy called TAK-007 in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. Participants first receive chemotherapy to lower certain white blood cells, then get one or three injections o…

This early-phase trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves 27 adults and focuses on safety and how w…

This phase 2 trial tests a combination of the immunotherapy drug glofitamab plus two chemotherapy drugs (gemcitabine and oxaliplatin) in 40 adults with refractory diffuse large B-cell lymphoma that did not respond to initial treatment. The main goal is to see how many patients ac…

This study tests a new type of CAR T cell therapy, called ALLO-501A, made from donor cells (not the patient's own). It is for adults with large B-cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma that has come back or not responded to other treatments. The …

This study tests an experimental oral drug, CC-99282, in people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. The drug is given alone or with other lymphoma medicines. The main goals are to check safety and find the best dose, while also seeing …

This phase 2 trial is testing an injectable form of the immunotherapy drug pembrolizumab (combined with hyaluronidase to help absorption) in 66 adults with classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma that has returned or not responded to prior treatmen…

This study tests an experimental drug called brincidofovir in people with lymphoma (a type of blood cancer) that has returned or not improved after standard treatments. The trial has two parts: first, finding a safe dose in up to 18 people with various lymphomas, then testing tha…

This study tracks how well the drug epcoritamab works for 150 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. Researchers will measure tumor shrinkage and side effects in everyday medical practice, not…

This phase 2 trial was designed to test a combination of rituximab, venetoclax, and bortezomib in patients with diffuse large B-cell lymphoma that had come back or stopped responding to treatment. The goal was to see how many patients would have their tumors shrink or disappear. …

This study tests a modified intravenous dosing schedule of tafasitamab combined with oral lenalidomide in 53 adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for a stem cell transplant. The main goal is to evaluate safety and how the drug move…

This study tests a new stem cell treatment (MGTA-456) made from umbilical cord blood for people with high-risk blood cancers like leukemia and lymphoma. About 22 patients will receive high-dose chemotherapy followed by the stem cell infusion. The goal is to see if this treatment …

This study tests a combination of two drugs, copanlisib and venetoclax, in about 48 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to find the safest dose and see how well the drugs shrink tumors. Participants must ha…

This early-stage study is testing an experimental drug called JS203 in about 104 people with relapsed or refractory B-cell non-Hodgkin's lymphoma, a type of blood cancer. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shrinkin…

This study looks at whether giving more stem cells during an autologous transplant helps people with relapsed or refractory diffuse large B-cell lymphoma recover better and stay cancer-free longer. About 59 adults who have already tried one chemotherapy will get high-dose chemo (…

This study aimed to test the drug selinexor combined with other treatments for people with a type of blood cancer called diffuse large B-cell lymphoma that had come back or stopped responding to therapy. The trial was planned in two phases to first find the safest dose and then c…

This early-phase trial is testing whether combining two drugs—nivolumab (a monoclonal antibody) and lenalidomide (a chemotherapy-like drug)—can safely and effectively treat people with non-Hodgkin or Hodgkin lymphoma that has returned or is not responding to treatment. The study …

This early-phase trial is testing a new type of immunotherapy for people with B-cell Non-Hodgkin's lymphoma that has returned or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in the lab to target two proteins (CD19 and CD20) on canc…

This early-phase study tests a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in 22 patients with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and see how well the body tolerates the c…

This study tracks 40 patients with aggressive B-cell lymphoma who have received CAR-T cell therapy. Researchers take a blood sample 7 days after treatment to look for leftover tumor DNA. The goal is to see if they can report results within 3 weeks, giving doctors a head start to …